The only NARI that has been licensed for use in the UK is reboxetine. A recent meta-analysis 8 suggested that reboxetine was less effective than either placebo or SSRIs for the treatment of depression. Yet, an earlier publication by Papakostas et al 9 that included data from four unpublished randomised controlled trials (RCTs) reached a different conclusion and reported no significant difference in response rates between reboxetine and SSRIs. This discrepancy has been acknowledged but not explained. 8 Of note, Eyding et al 8 found considerable heterogeneity in the metaanalysis of the eight RCTs comparing response rates for reboxetine v. placebo. This could not be fully explored as Eyding et al 8 only had access to aggregate data but there was evidence that reboxetine was more effective than placebo among in-patients with current depression. Such individuals would be expected to have more severe illness than the community patients customarily recruited into modern regulatory trials of new antidepressants. Others have also reported a greater drug-placebo difference in individuals with more severe depression. 10 Two other studies have suggested that NARIs are more effective in the more severe depressions. 11, 12 Historically, the presence of 'endogenous' or 'biological' symptoms were used as clinical indications for the prescription of antidepressants and such symptoms are viewed as markers of severity. 13 The Genome Based Therapeutic Drugs for Depression (GENDEP) study has reported that even though overall outcome (as measured by scores on the Beck Depression Inventory (BDI)) was similar between
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Severity of depression and response to antidepressants: GENPOD randomised controlled trial Nicola J. Wiles, Jean Mulligan, Tim J. Peters, Philip J. Cowen, Victoria Mason, David Nutt, Deborah Sharp, Debbie Tallon, Laura Thomas, Michael C. O'Donovan and Glyn Lewis Background Antidepressant prescribing is widespread. Nonetheless, response to antidepressants is variable. If it was possible to predict response to medication and thus tailor treatment accordingly, this would not only improve patient outcomes but may also have economic benefits.
Aims
To test the hypothesis that individuals with more severe depression would benefit more from noradrenaline reuptake inhibitors (NARIs) than selective serotonin reuptake inhibitors (SSRIs) compared with individuals with less severe depression.
Method
Individuals recruited from UK primary care who met ICD-10 criteria for a depressive episode and scored 15 or more on the Beck Depression Inventory (BDI) were randomised to either an SSRI (citalopram 20 mg daily) or a NARI (reboxetine 4 mg twice daily). Randomisation was by means of a remote automated telephone system. The main outcome was depressive symptoms measured by the BDI total score 6 weeks after randomisation. (Trial registration: ISRCTN31345163.)
Results
In total, 601 participants were randomised (citalopram: n = 298, reboxetine: n = 303). Ninety-one per cent were followed up at 6 weeks (citalopram: n = 274, reboxetine: n = 272). There was little evidence to support an interaction between treatment and severity of depression (interaction term: 0.02, 95% CI 70.59 to 0.62, P = 0.96). Adjustment for potential confounders (age, gender, employment status, history of depression, number of life events and social support) did not affect the findings (interaction term: 0.06, 95% CI 70.54 to 0.66, P = 0.85).
Conclusions
Treatment with NARIs does not confer any advantage over SSRI treatment for outcome in those with more severe depressive illness presenting in primary care.
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escitalopram and nortriptyline, the latter, a tricyclic antidepressant that predominantly blocks the reuptake of noradrenaline, led to more improvement in 'neurovegetative' symptoms of sleep, appetite and sexual interest and less improvement in mood and cognitive symptoms.
14 However, GENDEP did not examine whether severity of depression predicted (primary) treatment response and there is little other literature in this area. 15 The GENetic and clinical Predictors Of treatment response in Depression (GENPOD) study was designed to test two primary hypotheses: (a) those with the 'l/l' genotype of 5-HTTLPR would respond better to an SSRI than a NARI; and (b) those with more severe depression would show better response to a NARI than an SSRI. Importantly, given that the primary analyses were based on tests for interaction (that is, subgroup analyses), sample size was calculated accordingly. The primary outcome, principal comparisons and method of analysis were specified in advance as advocated in CONSORT guidelines. 16 The results for one of the primary hypotheses, the genetic predictor of treatment response, have already been reported. 17 The current paper reports the findings for the clinical predictor (the other primary hypothesis for the GENPOD study). We hypothesised that individuals with more severe depression would benefit more from NARIs than SSRIs compared with those with less severe depression.
Method
The GENPOD trial
The trial protocol has been published elsewhere. 18 In brief, GENPOD was a multicentre RCT conducted in Bristol, Birmingham and Newcastle, UK. Individuals aged 18-74 years were referred to GENPOD by their general practitioner (GP) following agreement that an antidepressant should be prescribed. Participants were randomly allocated to receive either an SSRI (citalopram 20 mg daily) or a NARI (reboxetine 4 mg twice daily). Only those individuals who met ICD-10 19 criteria for a depressive episode (F32) from the computerised Clinical Interview Schedule -Revised (CIS-R) 20, 21 and had a Beck Depression Inventory (BDI) 22, 23 score of 515 at the baseline assessment were eligible to participate.
Individuals who had taken antidepressant medication in the 2 weeks prior to the baseline assessment were excluded, as were those who could not complete self-administered questionnaires. General practitioners also excluded those with medical contraindications, psychosis, bipolar disorder, major substance or alcohol misuse and others whose participation was deemed inappropriate.
Ethical 
Randomisation procedure
Following the baseline assessment, eligible participants were asked to give written informed consent to randomisation. Randomisation was conducted by means of a computer-generated code, administered centrally and communicated by telephone, thereby concealed in advance from the recruiting researcher. Allocation was stratified by severity of overall symptoms (CIS-R total score 528 or 528) and centre using variable block sizes to maximise concealment. The researcher gave the allocated medication to the participant. Neither researchers nor participants were masked to the allocated treatment.
Allocated treatments
Participants randomised to citalopram were prescribed 20 mg daily. Citalopram taken at this dose has been shown to occupy about 80% of serotonin transporter reuptake sites, which is the level of occupancy apparently required to produce reliable antidepressant effects. 24 Those randomly allocated to reboxetine were advised to start on 2 mg twice daily and increase this to 4 mg twice daily after about 4 days. Research has shown that acute doses of 4 mg of reboxetine increases cortisol levels indicative of increased noradrenergic function. 25 Further, reboxetine at the same dose produces peripheral autonomic effects consistent with noradrenaline reuptake blockade. 26 All participants were advised to contact their GP if they wished to increase the dose of their medication.
Outcome measures
Outcome data were recorded 6 and 12 weeks after randomisation. All outcomes were self-administered. The primary outcome was the total BDI score at 6 weeks. Secondary outcomes have been described elsewhere. 18 In the present paper, we also report the proportion 'in remission' (defined as a total BDI score 510) at 6 weeks, 12-item Short-Form Health Survey (SF-12) 27 mental and physical subscale scores and Hospital Anxiety and Depression Scale (HADS) 28 total scores. Adherence with medication was assessed at 6 weeks by both self-report and a pill count of returned medication.
Self-administered outcomes were used rather than clinicianadministered measures such as the Hamilton Rating Scale for Depression (HRSD) 29 because of the potential for bias in a non-masked trial such as this.
Severity of depression
The CIS-R 20,21 is a fully structured interview that measures 14 symptom groups and, as well as generating ICD-10 diagnoses, the CIS-R also generates a total symptom score (0-57). The assessment asks questions about the week prior to interview and the onset and duration of each episode. In order to address the specified hypothesis, the severity of depression (CIS-R dep ) was calculated as the sum of the scores for the following CIS-R items: depression, depressive ideas, fatigue, concentration and sleep (score range: 0-21).
Statistical analysis
The Trial Steering Committee agreed the analysis plan prior to the analyses being conducted. As described earlier, the GENPOD study was designed to test two primary hypotheses. The findings in relation to genetic predictors of treatment response have been reported elsewhere. 17 The description of the analysis that follows is specific to the current hypothesis relating to severity and outcome. All analyses were conducted using Stata version 11.1 for Windows.
The primary analysis was a pre-specified subgroup analysis for the primary outcome of BDI score at 6 weeks, with analysis performed on an intention-to-treat (ITT) basis. A linear regression model was generated that included an interaction term between treatment (citalopram/reboxetine) and the predictor (severity of depression, CIS-R dep ) as a continuous variable. The model was adjusted for baseline BDI score, centre and the stratification variable of CIS-R total score (528 or 528). A further secondary analysis was conducted including only those participants who reported taking their allocated medication for at least 4 weeks. Analyses were repeated adjusting for the time between randomisation and follow-up by incorporating it as a continuous variable in the models. Further adjustment was also made for potential confounders: sociodemographic factors (age, gender and employment status), history of depression, life events and social support. All differences were calculated by subtracting BDI scores for the citalopram group from those in the reboxetine group (so a positive value indicates a worse outcome for reboxetine).
Different instruments have been used to measure depressive symptoms in prior studies making direct comparison of the severity of participants' depression difficult. Therefore, an additional analysis that was not part of the original analysis plan was also conducted to test for differential effects in individuals with more severe depression. This was defined, a priori, as those in the top 10% of the CIS-R depression severity scale, CIS-R dep .
Additional analyses (included in the original analysis plan) were undertaken for the secondary outcomes of BDI remission, HADS total score, SF-12 physical and mental subscale scores. Adjustment for baseline score, stratification variables and potential confounders were made as described earlier. For the binary outcome of 'remission', the reported odds ratios are the ratio of the odds of remission for those on reboxetine/citalopram so an odds ratio of more than one indicates a better outcome with reboxetine. Repeated measures linear/logistic regression was used to include data from both 6 and 12 weeks with a variable denoting time (6/12 weeks) in the regression model, together with the other adjustments mentioned in the primary analysis.
Finally, the baseline characteristics of those with or without outcome data at 6 weeks were compared. Missing data may not only result in a loss of precision but also introduces the potential for bias. The impact of missing data, primarily outcome data, on the findings was examined by adjusting for factors associated with 'missingness' in the various regression models. This method should address any bias under a missing at random assumption. 30 Justification of the sample size Details of the sample size calculations for the trial and the impact of the final recruitment figures on the power of the study were given in the protocol paper. 18 The sample size was primarily driven by the genetic hypothesis 17 with a revised target of 570 participants set for the primary analysis. The original power calculations for the severity hypothesis assumed that 44% of participants would be classified as having 'severe' depression. In order to detect a differential effect of 75% remission in the low severity/SSRI and high severity/NARI groups compared with 55% remission in the other two groups, a total of 282 participants was required. Thus, the GENPOD trial was adequately powered to address the question of the differential response to treatment based on the severity of depression (that is, the interaction between severity and treatment allocation).
Results

Trial participation and follow-up
The CONSORT flow chart and baseline comparability of the randomised groups for the GENPOD trial has been published previously. 17 In total, 601 participants were randomised to receive either citalopram (n = 298) or reboxetine (n = 303) between October 2005 and February 2008. The mean age of participants was 38.8 years (s.d. = 12.4) and 68% (n = 408) were female. Ninety-two per cent of participants (n = 550) had moderate (n = 305) or severe depression (n = 245) according to ICD-10 criteria.
Ninety-one per cent (n = 546) completed the 6-week follow-up (citalopram: n = 274, reboxetine: n = 272) and 81% (n = 486) completed the 12-week follow-up (citalopram: n = 253, reboxetine: n = 233).
Adherence to medication
Adherence to medication was higher among those randomised to citalopram at 6 weeks (on medication: citalopram n = 246 (83%), reboxetine n = 193 (64%)) and 12 weeks (on medication: citalopram n = 205 (69%), reboxetine n = 141 (47%)).
General practitioners increased the dose of citalopram for 55 participants (20%) (from 20 mg to: 30 mg (n = 11), 40 mg (n = 33) and to 60 mg (n = 11)). A smaller number of those allocated to reboxetine (n = 13 (5%)) also had their dose of medication increased (from 4 mg twice daily to: 10 mg (n = 3), 12 mg (n = 9) and to 16 mg (n = 1)).
Baseline comparability of severity groups
Those with more severe depression were less likely to be employed (full or part time), have experienced more life events in the previous 6 months, and report lower levels of social support compared with those with less severe depression ( Table 1) . Those with more severe depression were slightly younger, more likely to be male and have a history of depression. However, there were no differences in terms of ethnicity, prior treatment with antidepressants or family history of depression according to severity of depression at baseline (Table 1) .
Analysis for the severity hypothesis
The mean BDI scores at 6 weeks are given in Table 2 together with the differences between citalopram and reboxetine according to severity of depression. The primary analysis investigated the interaction between severity (as a continuous variable) and allocated treatment, with BDI score at 6 weeks as the outcome, adjusting for baseline BDI and stratification variables used in randomisation (CIS-R stratum and centre). This provided no evidence of a differential effect (interaction term: 0.02, 95% CI 70.59 to 0.62, P = 0.96). Adjusting the primary analysis for the time interval between randomisation and the 6-week follow-up had no effect (interaction term: 0.02, 95% CI 70.59 to 0.62, P = 0.95). Similarly, there was little evidence to support an interaction between treatment and severity of depression following adjustment for potential confounders (age, gender, employment status, history of depression, number of life events and social support) (interaction term: 0.06, 95% CI 70.54 to 0.66, P = 0.85). Results from analyses that were restricted to the 474 participants who took their allocated medication for at least 4 weeks were consistent with the findings of the primary analysis (interaction term: 0.09, 95% CI 70.56 to 0.74, P = 0.79 (adjusted for stratification variables, baseline BDI score and the potential confounders listed earlier)).
We also investigated a main effect of severity on outcome, irrespective of treatment, after adjustment for the random allocation, baseline BDI score and stratification variables. On average, a one unit increase in the CIS-R depression severity score was associated with a 0.45 unit increase in BDI score at 6 weeks adjusting for baseline (coefficient 0.45, 95% CI 0.05 to 0.85). However, following adjustment for potential confounders, the magnitude of this effect attenuated and the 95% confidence interval included the null (coefficient: 0.39, 95% CI 70.02 to 0.79).
An additional analysis that was not part of the original analysis plan was also conducted. The most severe 10% of respondents scored 519 on the CIS-R depression severity scale (CIS-R dep ) and this threshold was used to test for differential effects in participants with more severe depression. At baseline, mean BDI scores for the two groups were as follows: CIS-R dep 519: n = 528, mean BDI score: 32.5 (s.d. = 9.1); CIS-R dep 519: n = 73, mean BDI score: 42.0 (s.d. = 9.6). The mean BDI scores at 6 weeks are given in Table 3 together with the differences between citalopram and reboxetine according to severity of depression. Linear regression analysis was repeated with the BDI at 6 weeks as the outcome, adjusting for baseline BDI score, stratification variables and potential confounders to test for an interaction between allocated medication and severity (CIS-R dep 519 v. 519). In this analysis, the outcome in the lower severity group was worse for those randomised to reboxetine, whereas reboxetine was better for those with more severe depression (Table 3) . There was weak evidence of an interaction between treatment and severity and BDI outcome at 6 weeks (interaction term: 75.07, 95% CI 710.4 to 0.27, P = 0.063) following adjustment for stratification variables and potential confounders. Among those with the most severe depression (CIS-R dep 519), scores on the BDI for those who received reboxetine, on average, improved by 2.7 points more than those who received citalopram (Table 3) . However, this improvement represented less than a third of a standard deviation change relative to the baseline BDI score for this group.
The influence of severity on outcome was also examined in repeated measures analyses that included data from both 6-and 12-week follow-ups. Again, there was no evidence to support an interaction between severity as a continuous variable and treatment allocation (interaction term: 0.09, 95% CI 70.47 to 0.65, P = 0.75) adjusted for stratification variables and potential confounders, as described earlier. However, in the repeated measures analysis examining the interaction between treatment and a binary indicator of the most severe depressions (CIS-R dep 519 v. =19), there was some evidence that those with the most severe depression were more likely to benefit from reboxetine (interaction term: 75.28 (95% CI 710.2 to 70.36), P = 0.04).
Secondary outcomes
Analyses were repeated for the secondary outcomes of HADS, SF-12 physical and mental subscales scores (online Tables DS1-3) , with adjustment for the stratification variables and potential confounders listed earlier. There was no evidence to support an interaction between severity and outcome for HADS (interaction term: 0.15, 95% CI 70.30 to 0.61, P = 0.51), SF-12 physical subscale scores (interaction term: 0.09, 95% CI 70.36 to 0.53, P = 0.69) or SF-12 mental subscale scores (interaction term: 70.24, 95% CI 70.95 to 0.46, P = 0.49). Repeated measures analyses were also conducted using data from both the 6-and 12-week follow-ups as described earlier. Again, there was no evidence to support an interaction between severity and treatment allocation (interaction terms: HADS 0.10, 95% CI 70.32 to 0.52, P = 0.65; SF-12 physical subscale 0.30, 95% CI 70.10 to 0.69, P = 0.14; SF-12 mental subscale 70.24, 95% CI 70.86 to 0.37, P = 0.44). Finally, the proportion of patients in 'remission' (BDI score 510) at 6 weeks is presented in Table 4 according to severity stratum. There was no evidence of a differential effect of severity on remission outcomes (interaction odds ratio (OR) = 0.99, 95% CI 0.85-1.15, P = 0.88) adjusted for all stratification variables and potential confounders, as previously). Results of repeated measures analyses also showed no evidence to support an interaction (interaction OR = 0.92, 95% CI 0.74-1.14, P = 0.43).
Missing data
Attrition was low, with less than 10% of participants lost to follow-up 6 weeks after randomisation. However, those lost to follow-up at 6 weeks were younger and reported more life events at baseline (online Table DS4 ). Both of these factors were included in the list of potential confounders that were adjusted for in the main analyses, and hence no further analyses were deemed necessary.
Discussion
Main findings
The study was designed to test the hypothesis that individuals with more severe depression would benefit more from NARIs than SSRIs. However, there was very little evidence to support this. Most of the participants in GENPOD had moderate or severe depression according to ICD-10 criteria. Only when we restricted the analysis to examine treatment response among the most severely affected (top 10% CIS-R dep : mean BDI score 42) was there weak evidence to support the hypothesis. Even among this group, the mean difference in BDI scores after 6 weeks of treatment for those on reboxetine compared with citalopram represented a reduction of less than a third of a standard deviation, which is an effect size often cited as clinically relevant. It is possible that a more refined method of identifying a subgroup of individuals with depression -for example, by identifying those with endogenous or biological symptoms -could be of value. However, we can conclude that, for the vast majority of those attending UK primary care with depression, which is the setting in which most depression is treated, treatment with NARIs does not confer any advantage for outcome in those with more severe illness.
Strengths and limitations
The main strength of the study was the measures taken to reduce the possibility of a chance finding. This included prior publication of the trial protocol and hypotheses, and agreement of a pre-specified analysis plan that restricted opportunities for multiple testing and selective reporting. Furthermore, the sample size calculation for the GENPOD study was primarily driven by the genetic hypothesis, 17 and hence the number of participants recruited was more than adequate to ensure that the study was adequately powered to address the hypothesis relating to severity and treatment response. In fact, the study recruited more than twice the number of participants that were required for these analyses (due to the larger numbers required for the other main hypothesis).
Non-adherence to the allocated treatment may have resulted in an underestimate of the influence of severity on outcome. Nevertheless, when analyses were restricted to those who took at least 4 weeks of medication, the findings did not differ. Followup rates were high (91% at 6 weeks), but even a small amount of missing data may introduce bias. However, adjustment for factors associated with missing data did not materially affect the findings.
Allocated medications were prescribed at doses that are standard for UK primary care (http://bnf.org/bnf/index.htm). General practitioners retained clinical responsibility for patient care throughout the GENPOD study and were free to increase the dose of allocated medication where appropriate and, indeed, the dose of medication was increased for 20% of GENPOD participants. The majority of participants in GENPOD were taking a lower dose of citalopram than used in the large US STAR*D study (primary care settings: mean exit dose 40.6 mg/ day). 4 Generally, 20 mg/day of citalopram is regarded as the minimum effective dose 31 and there is no evidence that 40 mg/ day is more effective at reducing depressive symptoms than 20 mg/day. 32 However, citalopram is a racemic mixture and there is evidence that its action at the serotonin transporter may be inhibited by the otherwise inactive R-enantiomer. 32 This may have implications for the efficacy of citalopram relative to certain other antidepressants. Finally, it is important to consider the generalisability of these trial findings. It is difficult to recruit a truly representative sample of individuals with depression. As has been previously reported, 17 GPs referred a total of 842 patients to the GENPOD study over a period of 28 months. The mean BDI scores in GENPOD are similar to other UK depression trials conducted in primary care 33, 34 and the large GENDEP study that ran in nine European centres.
14 In addition, the response rate to antidepressants in GENPOD was similar to the large US STAR*D study, 4 which aimed to recruit a representative sample of individuals with depression in the US healthcare system. Furthermore, published formula 35 enable the conversion of HRDS scores commonly used in US studies with the CIS-R scores available for GENPOD. The mean HRSD score of 22-23 reported in STAR*D 4 and other major US trials of cognitive-behavioural therapy v. antidepressant medication 36 or combinations of medication for depression 37 is equivalent to a CIS-R score of 23-24, which is slightly lower than the mean of 31 in GENPOD. 17 Thus, it would seem reasonable to generalise our findings to other European and US populations of people with depression seen in primary care and out-patient settings.
Comparisons with existing literature
Others have found that NARIs are more effective in the most severely affected individuals. 11, 12 Massana et al 11 found that, among participants who were rated the most severely ill at baseline, those randomised to reboxetine experienced a greater reduction in scores on the HRSD rating scale compared with those randomised to receive fluoxetine for 8 weeks. However, no formal test of an interaction of treatment by severity was undertaken. Venditti et al 12 combined data from two 8-week multinational trials with a specific focus on the outcome of self-rated social functioning and found that reboxetine was more effective in improving social functioning for the more severely ill participants after 4 weeks of treatment, although this difference diminished with time. However, Venditti et al 12 incorporated the severity of depression in the participants measured during the trial in the regression model rather than focusing on a baseline measure of severity as a predictor of outcome.
Different instruments were used to measure depressive symptoms in these studies, thus it is difficult to directly compare the severity of participants' depression. However, converting scores as above demonstrates that the samples in these trials were similar to GENPOD (mean HRSD: 27-29 equivalent to CIS-R scores [29] [30] [31] . 35 Nonetheless, in the findings described above, severity of depression was measured using the Clinician Global Impression -Severity of Illness scale (CGI-SI), and it is difficult to directly compare this measure to the CIS-R depression scale used in the present analyses. Although the CGI-SI will reflect the severity of symptoms, such a rating may also capture the impact of the depressive symptoms on the individual. Thus, it may be that the anecdotal clinical evidence that those with more severe depression are more likely to respond to treatment with NARIs may reflect a more global view of severity, which would align with the CGI-SI measure and thus the evidence from prior studies 11, 12 rather than GENPOD. Others have suggested that, rather than improve mood, different antidepressants may lead to improvement in different symptoms. For example, in the GENDEP study, the tricyclic antidepressant nortriptyline led to more improvement in sleep, appetite and sexual interest and less improvement in mood and cognitive symptoms.
14 It is possible that such effects may have been overlooked in the present analyses as the measure of severity used combined scores on a range of symptoms (including depressive ideas, fatigue, concentration and sleep).
As discussed earlier, a recent meta-analysis 8 suggested that reboxetine was less effective than either placebo or SSRIs for the treatment of depression but this was at odds with an earlier publication that reported no difference in response rates between reboxetine and SSRIs. 9 Moreover, there was evidence that reboxetine was more effective than placebo among in-patients 8 who would be likely to have more severe depression. 8 Even if we assume that reboxetine is a less effective treatment, then this would have made it more likely that we would have found an interaction between severity of depression and treatment allocation, in contrast to our findings. Moreover, drop-out from treatment is higher with reboxetine compared with SSRIs. 7, 8 Such differential non-adherence needs to be accounted for in order to obtain valid estimates of the comparative efficacy of different treatments. Methods to allow for this have recently been proposed 38 but, to the best of our knowledge, no such allowances were made in the previous comparisons. 7, 8 Indeed, the approach by Cipriani et al 7 of assuming non-response to treatment may, in the presence of differential adherence, introduce bias such that reboxetine appears less effective.
Implications and further research
The ability to tailor treatments is key in the drive towards stratified medicine. 5 Not only would this speed recovery for individuals but it would have economic benefits. The GENPOD study was designed to test the hypothesis that individuals with more severe depression (measured at entry to the study) would benefit more from NARIs rather than SSRIs. However, there was very little evidence to support this in individuals with depression seen in primary care. Given the multifaceted nature of depressive illness, perhaps it is not surprising that a single factor in isolation is not predictive of treatment response. More consideration of the wider picture in terms of biological, psychological and social factors may be required in order to move towards the goal of tailoring treatment. Furthermore, it may be useful to focus on examining different patterns of symptoms that may have greater value in discriminating outcomes.
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